JOURNAL OF DERMATOLOGICAL CASE REPORTS, cilt.9, sa.2, ss.45-47, 2015 (ESCI)
Background: Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR).